复旦张江 (688505)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Listing Date2020-06-19
Issue Price8.95RMB
Registered Capital10365.72110k RMB
Legal RepresentativeZhao Dajun
Registered AddressNo. 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai
IndustryChemical Pharmaceuticals
Main BusinessMainly engaged in innovative R&D, production, and marketing of biopharmaceuticals.
Company ProfileShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. was founded in November 1996 in the Zhangjiang Hi-Tech Park, Pudong, Shanghai. Renowned enterprises and universities such as Shanghai Pharmaceutical Group Co., Ltd., New Enterprise Associates (NEA) Phase II Venture Capital, and Shanghai Fudan Asset Management Co., Ltd. are shareholders of the company.
Guided by the belief that "our further exploration brings more health to mankind," the company is primarily engaged in innovative research, development, production, and sales of biopharmaceuticals, striving to become an innovative biopharmaceutical enterprise with intellectual property as its core source. After years of relentless effort, the company has continuously introduced new technologies and products in fields such as genetic engineering drugs, photodynamic drugs, and nanomedicines, forming a distinct competitive advantage. It is expected that new drugs will be successively launched to the market in the future.
Leveraging its strength in the biopharmaceutical field, the company has undertaken multiple national key projects, including the "National Key Science and Technology Project (攻关) Plan," the "National High-Tech R&D Program (863 Program)," and the "National Science and Technology Major Project for Significant New Drugs Creation." Since 1998, the company has been consecutively recognized as a "High-Tech Enterprise" in Shanghai. In 1999, it was approved by the former Ministry of Personnel as a "Postdoctoral Research Workstation for Enterprises." In August 2002, the company was successfully listed on the Hong Kong Growth Enterprise Market (Stock Code: 8231).
Stock Details
1. Key Indicators
- Total Shares(W): 103657.21
- Circulating A-Shares(W): 71057.21
- Earnings Per Share(RMB): -0.0200
- Net Assets Per Share(RMB): 2.1786
- Operating Revenue(W RMB): 55107.53
- Total Profit(W RMB): -1613.27
- **Net Profit Attributable to Parent(W RMB) **: -1593.65
- Net Profit Growth Rate(%): -118.43
- Weighted Return on Equity(%): -0.7000
- Operating Cash Flow Per Share(RMB): 0.1020
- Undistributed Profit Per Share(RMB): 0.7889
- Capital Reserve Per Share(RMB): 1.2450
2. Main Business
The main business covers:
- Innovative R&D of biopharmaceuticals
- Manufacturing
- Marketing
3. Company Basic Information
- Company Name: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Listing Date: 2020-06-19
- Industry: Pharmaceutical Manufacturing
- Address: No. 308, Cailun Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai
- Website: https://www.fd-zj.com/
- Company Profile: The company was established through the legal overall change of Fudan Zhangjiang Limited, and is primarily engaged in the innovative R&D, manufacturing, and marketing of biopharmaceuticals.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | New Enterprise II Venture Capital Enterprise | General Legal Person | 15689.29 | 22.08 |
| 2 | Shanghai Pudong Emerging Industry Investment Co., Ltd. | General Legal Person | 656.24 | 0.92 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 364.95 | 0.51 |
5. Concept Sectors
- H-Share
- Gene Concept
- Generic Drug
- Innovative Drug
- Margin Trading & Securities Lending
- University Background
- Proposed Reduction
- Sci-Tech Innovation Board Biotech
- Sci-Tech Innovation Board SOE
- Sci-Tech Innovation 200
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information